Close

ISIS Financial Facts

Total revenue: 110.93M
Basic net loss (in dollars per share): 0.06
See Full Income Statement

Current portion of long-term obligations: 49K
Total current assets: 730.33M
See Full Balance Sheet

Isis Pharmaceuticals, Inc. (ISIS) Earnings

  |   Expand Research on ISIS
Next EPS Date N/A EPS Growth Rate N/A
Average EPS % Beat Rate +296.6% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +4.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/6/12 Q312 -$0.37-$0.26 -$0.11$11.6M$23.11M N/A Details
11/9/15 Q315 -$0.30-$0.31 +$0.01$49.1M$52.93M N/A Details
5/6/14 Q114 -$0.27-$0.23 -$0.04$28.2M$35.12M N/A Details
11/7/11 Q311 -$0.27-$0.20 -$0.07$20.7M$25.33M N/A Details
5/8/12 Q112 -$0.24-$0.26 +$0.02$23.2M$22.72M N/A Details
11/7/14 Q314 -$0.23-$0.20 -$0.03$44.1M$45.8M N/A Details
2/28/14 Q413 -$0.21-$0.17 -$0.04$42.2M$34.2M N/A Details
11/5/13 Q313 -$0.21-$0.27 +$0.06$23.6M$19.82M N/A Details